Washington’s latest intelligence assessments and federal indictments reveal how India’s pharmaceutical industry has become entangled in the deadliest drug epidemic in American history.
For decades, India has proudly carried the title of “Pharmacy of the World” a country that supplies a significant portion of the globe’s vaccines and generic medicines. But a series of alarming developments in early 2025 have cast a long shadow over that reputation, as U.S. intelligence agencies, federal prosecutors, and policy experts increasingly point to India as an emerging and troubling player in the global fentanyl supply chain.
Fentanyl, a synthetic opioid that can be up to 100 times more potent than morphine, has become the leading driver of overdose deaths in the United States. It is the most common drug involved in overdose fatalities in the country, fueling an opioid crisis that has become a high-priority issue for the Trump administration. For years, China has been the main focus of U.S. counter-narcotics efforts, but a new front is opening — one that stretches from pharmaceutical labs in Hyderabad and Surat to the killing fields of the American heartland.
A Stark Intelligence Warning
The 2025 Annual Threat Assessment published by the Office of the Director of National Intelligence named India as the second-largest source country for illicit fentanyl precursor chemicals and pill-pressing equipment, behind China. The report stated that non-state groups are “often enabled, both directly and indirectly, by state actors, such as China and India as sources of precursors and equipment for drug traffickers.”
The trajectory is stark. The 2024 version of the same report had mentioned India only as a country where Mexican cartels were sourcing precursor chemicals “to a lesser extent,” while the 2023 report made no mention of India in relation to fentanyl at all. In just two years, India has moved from a footnote to the second line of a national security threat assessment.
A Federal Indictment
The intelligence report was not the only blow to India’s standing. Days before its release, the U.S. Department of Justice indicted Vasudha Pharma Chem Limited (VPC), a Hyderabad-based chemical manufacturing company, along with three of its senior employees — Chief Global Business Officer Tanweer Ahmed Mohamed Hussain Parkar, Marketing Director Venkata Naga Madhusudhan Raju Manthena, and Marketing Representative Krishna Vericharla — on multiple counts related to unlawfully importing fentanyl precursor chemicals into the United States.
The details of the indictment are striking. According to prosecutors, VPC advertised fentanyl precursor chemicals for sale worldwide on its website, in marketing materials, and at international trade shows. Between March and November 2024, the defendants allegedly sold an undercover federal agent 25 kilograms of N-BOC-4-piperidone (N-BOC-4P), a listed fentanyl precursor chemical, on two separate occasions.
The scale of the alleged operation is even more alarming. Between August and September 2024, the defendants reportedly negotiated a purchase of four metric tons of N-BOC-4P with the undercover agent two metric tons to be shipped to Sinaloa, Mexico, and another two metric tons to the United States for a total price of approximately $380,000, with the understanding that the chemicals would be used to manufacture fentanyl. Two of the defendants were arrested in New York City the morning the indictment was unsealed. If convicted, the individual defendants face a maximum penalty of 10 years in prison, while VPC faces fines of up to $500,000 per count.
A Problem Years in the Making
While the fentanyl connection has only recently come to the fore, experts have long warned that India’s opaque pharmaceutical sector and regulatory gaps were creating the conditions for exactly this kind of crisis. A 2018 analysis by the Center for Strategic and International Studies (CSIS) warned that India was already a central node in global illicit opioid networks specifically through the export of tramadol, a less potent but widely abused opioid.
Unlike China, which had by that point designated over 100 fentanyl variants and precursors on its controlled substances list, India had not placed fentanyl or most other opioids on any equivalent list. India regulated only 17 of the 24 basic fentanyl precursor chemicals outlined by the UN 1988 Convention against Drugs.
The CSIS analysis also warned that Indian tramadol networks had been linked to ISIS and Boko Haram, with seizures of tramadol from India destined for Islamic State territory. In one instance, $75 million worth of tramadol — approximately 37 million pills was intercepted in Italy en route to Libya, with ISIS identified as the buyer. The warning was prescient: those same commercial networks, regulatory blind spots, and export capabilities are now being implicated in the far more lethal fentanyl trade.
The CSIS report concluded that “as the world pays closer attention to fentanyl from China, there is room for another major supplier to the United States. India has been slow to regulate precursor chemicals and does not regulate fentanyl or tramadol. Indian traffickers have developed worldwide networks. The drug threat from India requires a greater level of U.S.-India cooperation because it is too high to ignore.” Seven years later, those warnings have taken on a new and urgent relevance.
Geopolitical Fallout
The timing of these revelations is deeply inconvenient for New Delhi. The U.S. was India’s largest trading partner in 2024, with bilateral trade reaching nearly $120 billion. The Trump administration has already imposed steep tariffs on China, Mexico, and Canada, citing their roles in the fentanyl crisis, and analysts warn that India could be next.
Indian economist Soumya Bhowmik noted that the intelligence report “may introduce complexities in India-US relations” and could “open the door for tougher rhetoric and potentially even targeted tariffs.” Prime Minister Narendra Modi visited Washington in February, where both sides pledged to deepen trade and security ties but the fentanyl file threatens to complicate that diplomatic progress.
India’s government has so far stayed quiet. New Delhi has not publicly commented on the Annual Threat Assessment, and the Ministry of External Affairs had not responded to press inquiries at time of publication. However, India’s Anti-Terrorist Squad in Gujarat did arrest two individuals in March linked to pharmaceutical companies for allegedly exporting illicit fentanyl precursors to Mexico and Guatemala a sign that domestic law enforcement is beginning to take the issue seriously.
The Path Forward
The core challenge is structural. India’s pharmaceutical sector is vast, globally integrated, and enormously important to international public health. The same industrial capacity that makes India a critical supplier of affordable generic medicines also makes it a potential source of controlled chemical precursors. Dismantling illicit networks without disrupting legitimate pharmaceutical trade requires the kind of granular regulatory cooperation that takes years to build.
What is clear is that the fentanyl crisis can no longer be framed as a China problem alone. As U.S. intelligence, federal prosecutors, and independent analysts all converge on the same conclusion, the pressure on India to act will only intensify. The question is whether New Delhi treats this as an opportunity to demonstrate the strength of its partnership with Washington or allows the issue to fester until it poisons one of the most consequential bilateral relationships of the 21st century.
Sources: CNN, U.S. Department of Justice, Center for Strategic and International Studies (CSIS)
